vs
Orthofix Medical Inc.（OFIX）与STONERIDGE INC（SRI）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是STONERIDGE INC的1.1倍（$219.9M vs $205.2M），Orthofix Medical Inc.同比增速更快（2.0% vs -6.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $2.6M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -7.4%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Stoneridge Inc是全球领先的电气电子元件、集成系统及传感器解决方案设计制造商，服务汽车、商用车、非道路设备与航空航天领域，产品可提升车辆安全性、运行效率、互联性与环保表现，业务覆盖全球核心市场。
OFIX vs SRI — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$205.2M
营收增速更快
OFIX
高出8.0%
-6.0%
自由现金流更多
OFIX
多$14.2M
$2.6M
两年增速更快
OFIX
近两年复合增速
-7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $205.2M |
| 净利润 | $-2.2M | — |
| 毛利率 | 71.1% | 16.2% |
| 营业利润率 | 0.2% | -14.4% |
| 净利率 | -1.0% | — |
| 营收同比 | 2.0% | -6.0% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $-2.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXSRI
| Q4 25 | $219.9M | $205.2M | ||
| Q3 25 | $205.6M | $210.3M | ||
| Q2 25 | $203.1M | $228.0M | ||
| Q1 25 | $193.6M | $217.9M | ||
| Q4 24 | $215.7M | $218.2M | ||
| Q3 24 | $196.6M | $213.8M | ||
| Q2 24 | $198.6M | $237.1M | ||
| Q1 24 | $188.6M | $239.2M |
净利润OFIXSRI
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $-9.4M | ||
| Q2 25 | $-14.1M | $-9.4M | ||
| Q1 25 | $-53.1M | $-7.2M | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | $-7.1M | ||
| Q2 24 | $-33.4M | $2.8M | ||
| Q1 24 | $-36.0M | $-6.1M |
毛利率OFIXSRI
| Q4 25 | 71.1% | 16.2% | ||
| Q3 25 | 72.2% | 20.3% | ||
| Q2 25 | 68.7% | 21.5% | ||
| Q1 25 | 62.8% | 21.2% | ||
| Q4 24 | 69.0% | 19.5% | ||
| Q3 24 | 68.7% | 20.8% | ||
| Q2 24 | 67.8% | 22.7% | ||
| Q1 24 | 67.5% | 20.2% |
营业利润率OFIXSRI
| Q4 25 | 0.2% | -14.4% | ||
| Q3 25 | -8.3% | -1.6% | ||
| Q2 25 | -7.9% | -1.1% | ||
| Q1 25 | -25.2% | -1.5% | ||
| Q4 24 | -5.3% | -2.0% | ||
| Q3 24 | -9.6% | 0.1% | ||
| Q2 24 | -12.5% | 1.4% | ||
| Q1 24 | -15.6% | 0.1% |
净利率OFIXSRI
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | -4.5% | ||
| Q2 25 | -6.9% | -4.1% | ||
| Q1 25 | -27.4% | -3.3% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | -3.3% | ||
| Q2 24 | -16.8% | 1.2% | ||
| Q1 24 | -19.1% | -2.6% |
每股收益（稀释后）OFIXSRI
| Q4 25 | $-0.05 | $-2.76 | ||
| Q3 25 | $-0.57 | $-0.34 | ||
| Q2 25 | $-0.36 | $-0.34 | ||
| Q1 25 | $-1.35 | $-0.26 | ||
| Q4 24 | $-0.76 | $-0.22 | ||
| Q3 24 | $-0.71 | $-0.26 | ||
| Q2 24 | $-0.88 | $0.10 | ||
| Q1 24 | $-0.95 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $66.3M |
| 总债务越低越好 | — | $180.9M |
| 股东权益账面价值 | $450.0M | $179.8M |
| 总资产 | $850.6M | $551.2M |
| 负债/权益比越低杠杆越低 | — | 1.01× |
8季度趋势，按日历期对齐
现金及短期投资OFIXSRI
| Q4 25 | $82.0M | $66.3M | ||
| Q3 25 | $62.9M | $54.0M | ||
| Q2 25 | $65.6M | $49.8M | ||
| Q1 25 | $58.0M | $79.1M | ||
| Q4 24 | $83.2M | $71.8M | ||
| Q3 24 | $30.1M | $54.1M | ||
| Q2 24 | $26.4M | $42.1M | ||
| Q1 24 | $27.0M | $48.4M |
总债务OFIXSRI
| Q4 25 | — | $180.9M | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | $201.6M | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXSRI
| Q4 25 | $450.0M | $179.8M | ||
| Q3 25 | $442.5M | $251.2M | ||
| Q2 25 | $458.3M | $260.5M | ||
| Q1 25 | $458.3M | $253.1M | ||
| Q4 24 | $503.1M | $245.3M | ||
| Q3 24 | $525.9M | $271.4M | ||
| Q2 24 | $546.0M | $270.5M | ||
| Q1 24 | $570.3M | $277.3M |
总资产OFIXSRI
| Q4 25 | $850.6M | $551.2M | ||
| Q3 25 | $832.6M | $632.1M | ||
| Q2 25 | $837.2M | $639.4M | ||
| Q1 25 | $823.1M | $657.4M | ||
| Q4 24 | $893.3M | $621.6M | ||
| Q3 24 | $867.9M | $662.5M | ||
| Q2 24 | $882.0M | $666.7M | ||
| Q1 24 | $906.0M | $675.4M |
负债/权益比OFIXSRI
| Q4 25 | — | 1.01× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | 0.82× | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $8.8M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $2.6M |
| 自由现金流率自由现金流/营收 | 7.6% | 1.3% |
| 资本支出强度资本支出/营收 | 4.9% | 3.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $12.2M |
8季度趋势，按日历期对齐
经营现金流OFIXSRI
| Q4 25 | $27.7M | $8.8M | ||
| Q3 25 | $12.4M | $3.6M | ||
| Q2 25 | $11.6M | $10.7M | ||
| Q1 25 | $-18.4M | $10.9M | ||
| Q4 24 | $23.7M | $19.2M | ||
| Q3 24 | $11.7M | $10.8M | ||
| Q2 24 | $9.0M | $8.7M | ||
| Q1 24 | $-18.6M | $9.1M |
自由现金流OFIXSRI
| Q4 25 | $16.8M | $2.6M | ||
| Q3 25 | $2.5M | $-2.7M | ||
| Q2 25 | $4.5M | $7.4M | ||
| Q1 25 | $-25.1M | $4.8M | ||
| Q4 24 | $15.2M | $14.0M | ||
| Q3 24 | $6.3M | $4.6M | ||
| Q2 24 | $-360.0K | $1.5M | ||
| Q1 24 | $-29.1M | $3.3M |
自由现金流率OFIXSRI
| Q4 25 | 7.6% | 1.3% | ||
| Q3 25 | 1.2% | -1.3% | ||
| Q2 25 | 2.2% | 3.3% | ||
| Q1 25 | -13.0% | 2.2% | ||
| Q4 24 | 7.0% | 6.4% | ||
| Q3 24 | 3.2% | 2.2% | ||
| Q2 24 | -0.2% | 0.6% | ||
| Q1 24 | -15.4% | 1.4% |
资本支出强度OFIXSRI
| Q4 25 | 4.9% | 3.0% | ||
| Q3 25 | 4.8% | 3.0% | ||
| Q2 25 | 3.5% | 1.4% | ||
| Q1 25 | 3.5% | 2.8% | ||
| Q4 24 | 4.0% | 2.4% | ||
| Q3 24 | 2.7% | 2.9% | ||
| Q2 24 | 4.7% | 3.0% | ||
| Q1 24 | 5.6% | 2.4% |
现金转化率OFIXSRI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.11× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
